Engineered Veterinary Vectored Immunotherapy and Vaccines: EVVIVAX

Just open a Bet365 account today and make a deposit http://abonuscode.co.uk Make a deposit of £10-£200 and then enter the 10-digit bonus code

Our Vision

  • Engineered Veterinary Vectored Immunotherapy and Vaccines: EVVIVAX
    EVVIVAX is a spin-off of Takis Biotech, a company developing a number of Innovative Immunotherapies

    EVVIVAX is at the forefront of nucleic-acid based therapies, process development, industrial scale production and clinical trial execution

    EVVIVAX stems from new, European platform technologies, aims to offer novel therapeutic avenues to pet cancer patients, with the strong translational potential to complement current human Immune-Oncology approaches in the next future.

Evvivax News

  • 10-12 Apr 2017

    10-12 Apr 2017 - EVVIVAX at the World Veterinary Vaccine Conference, Washington DC, USA Join us at t...
  • 7 Apr 2017

    7 Apr 2017: EVVIVAX Visiting PennVet, Philadelphia, USA Dr Luigi Aurisicchio, CEO at EVVIVAX and Pre...
  • 10-12 Oct 2016

    Barcelona, 10-12 October 2016: EVVIVAX will be at the World Veterinary Vaccine Meeting
  • 6 Sep 2016

    London, 6 September 2016:EVVIVAX has participated at the meeting "Comparative Oncology: The Next Fro...